99 results
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
7 Mar 24
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
6:06am
to be generally well-tolerated in the randomized withdrawal period with no new or unexpected safety signals.
Planned submission of a New Drug
S-3ASR
SLNO
Soleno Therapeutics Inc
2 Jan 24
Automatic shelf registration
4:06pm
and sought continued treatment with DCCR were eligible to receive DCCR in a long-term open-label safety extension study (C602). Top line results from
8-K
EX-10.1
619t91wyv9bs
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
90ti j4j1t7
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
8bh8kcwh mb5m6er8
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.1
rt5q5zvl20
26 Sep 23
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from
7:30am
8-K
e8qaw9mk4 gs6za5
26 Sep 23
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from
7:30am
8-K
EX-99.1
ee2r i6rif
10 Jul 23
Regulation FD Disclosure
4:06pm
8-K
EX-10.1
4q4f6l0m362tr sqkag
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-10.2
8ksf1d s8k
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-99.1
cgiy57ji y4utk
9 Nov 22
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
4:11pm